Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Sponsor: University of Zurich
Summary
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
Official title: Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
600
Start Date
2022-03-01
Completion Date
2026-06-30
Last Updated
2024-05-08
Healthy Volunteers
No
Conditions
Interventions
VOCABRIA 30Mg Tablet
CAB 30 mg Film-coated tablets
EDURANT 25Mg Tablet
RPV 25 mg film-coated tablets
Cabotegravir Injectable Suspension
CAB LA 600 mg prolonged release suspension for injection (3 mL)
Rilpivirine Injectable Suspension
RPV LA 900 mg prolonged release suspension for injection (3 mL)
Intact proviral DNA assay
HIV-1 latent reservoir size
Full-length sequencing
Proviral DNA
Locations (1)
University Hospital Zurich
Zurich, Switzerland